NUZ 2.38% 20.5¢ neurizon therapeutics limited

Ann: Phase IIb Dog Trial Achieves Interim Clinical Endpoints, page-120

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,467 Posts.
    lightbulb Created with Sketch. 1204
    I am by no means a legal expert, I am thinking that seeing that Elanco hold the composition of matter patents until 2022 or 23/2024 or when ever it is and we have no agreements or options in place to enable us to commercially develop an anti-viral MPL-based product against SARS CoV2 or COVID-19, we have bugger all chance of getting any grant money because we have no legal right to MPL until Elanco's patents run their course.

    On another note a little while back I took a swipe at Dr Richard Mollard.
    Dr Richard Mollard is the Chief Scientific Officer of PharmAust Limited and the Chief Executive Officer of subsidiary company Pitney Pharmaceuticals Pty Limited.

    In his rolls as the CSO of PharmAust and CEO of Pitney I would suggest that he would have been instrumental in the negotiating the testing at WEHI and 360 in Australia and Leiden in Holland at nominal cost and also negotiating the $890 odd grand for testing on MND. Definitely pulling his weight . Dr Mollard if you are a follower here please accept my apology/retraction.

    Good luck to all.
 
watchlist Created with Sketch. Add NUZ (ASX) to my watchlist
(20min delay)
Last
20.5¢
Change
-0.005(2.38%)
Mkt cap ! $99.76M
Open High Low Value Volume
20.5¢ 21.0¢ 20.5¢ $20.93K 102.1K

Buyers (Bids)

No. Vol. Price($)
1 36959 20.5¢
 

Sellers (Offers)

Price($) Vol. No.
21.0¢ 71032 2
View Market Depth
Last trade - 16.10pm 28/10/2024 (20 minute delay) ?
NUZ (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.